Velsera is a precision medicine technology company founded in 2023, focused on accelerating the discovery, development, and delivery of clinical and research insights through integrated AI-enhanced software and expert services. Its technical work spans genomics, clinical diagnostics, AI, data harmonization, and analytics - applied across pharmaceuticals, clinical diagnostics, NGS assay manufacturing, and non-profit organisations.
The company operates several technology platforms: Seven Bridges, a bioinformatics environment for analysis; Clinical Genomics Workspace, for clinical genomics interpretation and reporting; ARIA, a platform for multimodal data harmonization and analytics; and an IVD-grade Knowledgebase for variant interpretation. These products address end-to-end workflows from raw sequencing data through to clinically actionable reporting.
Velsera's platforms process over 250,000 NGS samples annually and serve more than 80 active clinical NGS lab customers. The company maintains a presence in the United States, Europe, and Asia.
